Get the Stockscreener App
4.52
2.59%
-0.12
After Hours:
4.51
-0.010
-0.22%
Cingulate Inc stock is traded at $4.52, with a volume of 150.87K.
It is down -2.59% in the last 24 hours and down -8.87% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
See More
Previous Close:
$4.64
Open:
$4.7
24h Volume:
150.87K
Relative Volume:
0.30
Market Cap:
$60.88M
Revenue:
-
Net Income/Loss:
$-27.71M
P/E Ratio:
-1.0607
EPS:
-4.2615
Net Cash Flow:
$-19.77M
1W Performance:
-0.88%
1M Performance:
-8.87%
6M Performance:
-23.26%
1Y Performance:
-17.82%
1-Day Range:
$4.46
$4.85
1-Week Range:
$4.46
$4.97
52-Week Range:
$3.16
$11.89
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.52 | 62.50M | 0 | -27.71M | -19.77M | -4.2615 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
CING|Cingulate Inc|Price:4.595|Chg%:-0.045 - TradingKey
Cingulate Inc (CING) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cingulate Inc (CING) Balance Sheet - TradingKey
Cingulate Inc (CING) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cingulate Inc (CING) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cingulate Inc. Revenue Breakdown – NASDAQ:CINGW - TradingView
CING|Cingulate Inc|Price:4.640|Chg%:-0.200 - TradingKey
Why Is CING Stock Jumping Over 4% In Overnight Trading? - Stocktwits
Cingulate Inc|Price:4.640|Chg%:-0.200 - TradingKey
Cingulate Inc (CING) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBIT forward of Cingulate Inc. – NASDAQ:CINGW - TradingView
Cingulate Inc (CING) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cingulate (CING) Registration filing Summary - Quartr
Form 4 Cingulate Inc For: 21 July By Investing.com - Investing.com South Africa
CING Q1 2026 Earnings: Wider-than-Expected Loss Reported; Stock Rises Despite No RevenueEarnings Trend Analysis - dars.gov.et
Cingulate enhances equity plan and updates board leadership - The Globe and Mail
Cingulate Inc. Files 8-K with SEC: Key Corporate Details, Emerging Growth Status, and Nasdaq Listing Information - Minichart
Cingulate Inc. Announces Board and Committee Changes, Effective July 9, 2026 - marketscreener.com
Cingulate (Nasdaq: CING) adds 625K incentive shares, CEO named chair - Stock Titan
Price to earnings forward of Cingulate Inc. – BOATS:CINGW - TradingView
CINGW Drops Nearly 10% as Warrants Continue Trading at Deeply Discounted LevelsWyckoff Upthrust - dars.gov.et
Cingulate (CING) Proxy Filing Summary - Quartr
Cingulate (CING) Proxy filing Summary - Quartr
CING Q1 2026 Earnings: Wider-than-Expected Loss Sends Shares LowerProfit Announcement - dars.gov.et
Enterprise value to revenue forward of Cingulate Inc. – NASDAQ:CING - TradingView
CING Q1 2026 Earnings: EPS Misses Estimates Amidst No Revenue, Stock DeclinesEarnings Seasonality - DonanımHaber
Cingulate, Inc. Warrant 2021-03.12.26 on Cingulate Financial Disclosures & SEC Filings - TradingView
Form 4 Cingulate Inc For: 2 July By Investing.com - Investing.com Canada
Cingulate (CING) EVP and CSO Raul Silva receives grant of 3,885 stock options - Stock Titan
Cingulate (NASDAQ: CING) Added to Russell 3000E® Index, Boosting Visibility and Growth in ADHD Market - Minichart
Cingulate added to Russell 3000E Index - Investing.com
Cingulate added to Russell 3000E Index By Investing.com - Investing.com Nigeria
Cingulate Inc. joins Russell 3000E® Index, boos... - Pluang
Index addition puts Cingulate (NASDAQ: CING) into the Russell 3000E - Stock Titan
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E® - GlobeNewswire
Cingulate Inc. (CING) Slides 8.4% as Selling Pressure IntensifiesVolume Oscillator - dars.gov.et
CING Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Clinical Stage Biotech Continues DevelopmentPeak Earnings Alert - dars.gov.et
Cingulate Inc. (CING) Surges 8.78% as Momentum Builds Near Key Resistance LevelPrice Momentum Stocks - dars.gov.et
CING News | CINGULATE INC (NASDAQ:CING) - ChartMill
CING Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Remains Focused on Pipeline Progress - dars.gov.et
Cingulate Inc.(NasdaqCM: CING) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Cingulate Inc.(NasdaqCM: CING) added to Russell 3000E Growth Benchmark - marketscreener.com
Cingulate Inc.(NasdaqCM: CING) added to Russell Microcap Index - marketscreener.com
Cingulate Inc.(NasdaqCM: CING) added to Russell 3000E Index - marketscreener.com
Cingulate, Inc. Actuals & Estimates (NASDAQ:CING) - TradingView
CING Forecast — Price Target — Prediction for 2027 - TradingView
Cingulate Inc (CINGW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CING Stock Price, Quote & Chart - ChartMill
CINGW Warrants Decline Marginally, Remain in Narrow Trading Band at Penny LevelsIV Crush Alert - dars.gov.et
CING Q1 2026 Earnings: Wider-Than-Expected Loss as Revenue Remains AbsentTangible Book Value - dars.gov.et
CING Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Reports Wider-than-Expected Loss - dars.gov.et
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):